Phase Holographic Imaging Signs New Distributor for Singapore and Malaysia

September 2, 2025
Language flag

Phase Holographic Imaging PHI AB (“PHI” or the “Company”), is proud to announce the appointment of a new distributor, Gaia Bioscience Pte Ltd, for Singapore and Malaysia. This strategic partnership marks a significant step in PHI’s expansion into Southeast Asia, strengthening and accelerating its presence in one of the world’s most dynamic life science markets.

The newly appointed distributor brings extensive experience in biomedical research technologies and a strong network within academic institutions, hospitals, and biotech companies across the region. Through this collaboration, PHI aims to provide enhanced access to its flagship product, the HoloMonitor® system, enabling researchers in Singapore and Malaysia to conduct long-term, non-invasive live cell imaging with unprecedented clarity and precision.

”Welcoming our new distributor in Southeast Asia is a key milestone in PHI’s strategy to extend our global reach”, says Patrik Eschricht, CEO of Phase Holographic Imaging. “This partnership strengthens our presence in Singapore and Malaysia, aligning with our commitment to make advanced live cell imaging technologies accessible to researchers worldwide.”

Gaia Bioscience Pte Ltd, headquartered in Singapore, is renowned for its commitment to advancing biomedical innovation and supporting research excellence throughout Southeast Asia. As an established distributor of scientific technologies, Gaia Bioscience collaborates closely with academic institutions, hospitals, and biotechnology companies to provide cutting-edge solutions for life science applications. By fostering partnerships and promoting the adoption of state-of-the-art products, Gaia Bioscience has played a pivotal role in accelerating scientific discovery and enabling breakthrough research across the region.

The partnership is expected to accelerate PHI’s growth in Asia and support cutting-edge research in cell biology, cancer, and regenerative medicine.

For more information, please contact:
Patrik Eschricht, CEO
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis

Subscribe to PHI news on cision.com

Latest News

A black and white image showing a closeup of the HoloMonitor

PHI provides an update regarding the development progress of the new generation of HoloMonitor®

Phase Holographic Imaging PHI AB (“PHI” or the “Company”), a leading provider of advanced holographic imaging solutions, is pleased to update the market on the development progress of its next-generation of HoloMonitor®, which is scheduled for launch before the end of 2025. With the forthcoming launch of the new generation of HoloMonitor®, the Company will be moving into more clinically focused applications and a new, larger market segment.
The HoloMonitor HoloLids are specially designed to eliminate image disturbances, caused by surface vibrations and condensation inside the cell culture vessel.

Interim Report 4 2024/25

This spring has been a dynamic and productive period for PHI, as our team and partners have made significant efforts on multiple fronts. Externally, our collaboration with Altium has focused on expanding our sales processes and networks and enhancing our market presence. Internally, our dedicated team has been advancing our ongoing regenerative medicine projects and refining our HoloMonitor technology.
A red pin on a blue map.

Phase Holographic: Proposal to amend the Altium Distribution Agreement

Phase Holographic Imaging PHI AB (“PHI” or the “Company”) announces that the Board of Directors has decided to call for an Extraordinary General Meeting to approve a proposed amendment of the distribution agreement with Altium SA (“Altium”), the Company’s global distributor and main shareholder.
See All News